Prediction of mortality in patients with coronary artery disease undergoing vasodilator stress testing:: A comparison between 99mTc-tetrofosmin and 99mTc-sestamibi

被引:1
|
作者
Adams, George L.
Shaw, Linda K.
Tuttle, Robert H.
Hanson, Michael W.
Pagnanelli, Robert
Borges-Neto, Salvador [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Med Cardiol, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27710 USA
关键词
vasodilator; SPECT; prognosis;
D O I
10.1097/MNM.0b013e328174442d
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose To compare the prognostic ability of the imaging agents Tc-99m-sestamibi versus Tc-99m-tetrofosmin to predict mortality outcomes in patients with documented coronary artery disease and undergoing vasodilator stress testing. Materials and methods The study included 2147 consecutive patients who underwent rest and stress single photon emission computed tomographic (SPECT) examination with either 99mTc-sestamibi (n= 1128) or Tc-99m-tetrofosmin (n=1019). Information relating to all-cause death and cardiovascular death was collected over a 4-year study period. Unadjusted Kaplan-Meier estimates were compared for the two imaging agents. Cox proportional hazard models were examined to determine the incremental contribution of SPECT sum stress score (SSS) and the imaging agent after adjusting for clinical and demographic characteristics. Additionally, the interaction between SSS and agent was examined to determine if the effect of SSS on prognosis was different for the two agents. Results Vasodilator agents were used for stress testing in all patients who received Tc-99m-tetrofosmin and Tc-99m-sestarnibi. Despite differences in patient risk factors Kaplan-Meier estimates were similar for the two groups of patients. Resulting P-values for differences between models for the end points of (1) death from any cause and (2) cardiovascular death showed that SSS combined with clinical index was significantly better than a model that adjusted for only baseline characteristics (P < 0.0001 for both endpoints). The addition of imaging agent (Tc-99m-tetrofosmin or 99mTc-sestamibi) to the model containing both SSS and the clinical characteristics did not show further significant improvement (P=0.62, P=0.96 for death from any cause and cardiovascular death, respectively). Conclusion The type of clinically available Tc-99m-labelled myocardial perfusion agents did not affect interpretation of results for prognostic assessment.
引用
收藏
页码:457 / 463
页数:7
相关论文
共 50 条
  • [31] Myocaridal scintigraphy with 99mTc-sestamibi in patients with Kawasaki disease
    Hwang, B
    Tsai, MC
    Lee, PC
    Fu, YC
    Jan, SL
    Chiu, PS
    Meng, CCL
    Chu, LS
    Liu, RS
    PEDIATRIC RESEARCH, 2003, 53 (01) : 184 - 184
  • [32] Myocaridal Scintigraphy with 99mTc-Sestamibi in Patients with Kawasaki Disease
    Betau Hwang
    Ming-Chih Tsai
    Pi-Chang Lee
    Yun-Ching Fu
    Sheng-Ling Jan
    Pao-Sheng Chiu
    CC Laura Meng
    Lee-Shing Chu
    Ren-Sheng Liu
    Pediatric Research, 2003, 53 : 184 - 184
  • [33] Efficiency comparison between 99mTc tetrofosmin and 99mTc sestamibi myocardial perfusion studies.
    Borges-Neto, S
    Hanson, MW
    Ravizzini, GC
    Wong, TZ
    Hagge, RJ
    Shaw, LK
    Coleman, RE
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 160P - 160P
  • [34] Significance of increased right ventricular uptake on 99mTc-Sestamibi SPECT in patients with coronary artery disease
    Mannting, F
    Zabrodina, YV
    Dass, C
    JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (06) : 889 - 894
  • [35] Comparison of diagnostic accuracy for breast cancer between 99mTc-tetrofosmin and 99mTc-MIBI scintimammography.
    Park, JM
    Choi, JY
    Lee, KH
    Choi, Y
    Choe, YS
    Yang, JH
    Nam, SJ
    Kim, SE
    Kim, BT
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 290P - 290P
  • [36] Reduction of 99mTc-sestamibi and 99mTc-tetrofosmin uptake in MRP-expressing breast cancer cells under hypoxic conditions is independent of MRP function
    Seigo Kinuya
    Xiao-Feng Li
    Kunihiko Yokoyama
    Hirofumi Mori
    Kazuhiro Shiba
    Naoto Watanabe
    Noriyuki Shuke
    Hisashi Bunko
    Takatoshi Michigishi
    Norihisa Tonami
    European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30 : 1529 - 1531
  • [37] Myocardial kinetics of 201Thallium, 99mTc-tetrofosmin, and 99mTc-sestamibi in an acute ischemia-reperfusion model using isolated rat heart
    Fukushima, Kenji
    Momose, Mitsuru
    Kondo, Chisato
    Kusakabe, Kiyoko
    Kasanuki, Hiroshi
    ANNALS OF NUCLEAR MEDICINE, 2007, 21 (05) : 267 - 273
  • [38] Reduction of 99mTc-sestamibi and 99mTc-tetrofosmin uptake in MRP-expressing breast cancer cells under hypoxic conditions is independent of MRP function
    Kinuya, S
    Li, XF
    Yokoyama, K
    Mori, H
    Shiba, K
    Watanabe, N
    Shuke, N
    Bunko, H
    Michigishi, T
    Tonami, N
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (11) : 1529 - 1531
  • [39] 99mTc-Sestamibi Thyroid Imaging in Patients on Chronic Amiodarone Treatment: a Comparison with 99mTc-Pertechnetate Imaging
    Oki, G. C.
    Zantut-Wittmann, D. E.
    Santos, A. O.
    Guariento, M. H.
    Tambascia, M. A.
    Amorim, B. J.
    Lima, M. C. L.
    Etchebehere, E. C. S. C.
    Camargo, E. E.
    Ramos, C. D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S373 - S373
  • [40] Cost analysis comparison between 99mTc tetrofosmin and 99mTc sestamibi myocardial perfusion imaging protocols
    Ravizzini, G
    Pagnanelli, RA
    Coleman, RE
    Borges-Neto, S
    RADIOLOGY, 2001, 221 : 612 - 612